Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer posts strong earnings despite Trump’s new 'up to 250%' tariff threat

Pfizer beat earnings expectations and improved its outlook for the rest of the year, despite fresh statements from Trump announcing pharma tariffs next week.

Euronews

Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact, Raises Outlook

On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.

Benzinga

Dow Surges Over 100 Points; Pfizer Earnings Top Views

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Tuesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Smashes Earnings Forecasts And Raises Outlook; Shares Jump

Pfizer stock jumped Tuesday after the S&P 500 pharma titan beat second-quarter expectations on the back of solid cost-cutting measures.

Investors Business Daily

Stock Market Today: Dow Retreats After Back-And-Forth Action; Palantir Makes This Bold Move (Live Coverage)

The major indexes ended the session in negative territory Tuesday.

Investors Business Daily

Stock Index Futures Gain on Strong Earnings and Fed Rate-Cut Bets

September S&P 500 E-Mini futures (ESU25) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.30% this morning, extending a rebound driven by bets on Federal Reserve interest rate cuts and solid corporate earnings.

Barchart

Option Volatility And Earnings Report For Aug 4 - 8

It’s another big week on the earnings front this week with some important companies set to report including Palantir, Advanced Micro Devices, Uber Technologies, Pfizer, Disney, Shopify, Arista Networks and McDonald’s.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Benzinga

Tariff wars: Has Donald Trump killed the WTO?

In the wake of Trump’s global trade war, can the World Trade Organization reclaim its role as guardian of free trade?

Al Jazeera

Seven all-American products that are actually 'Made in Europe', set to be hit by US tariffs

Trump’s tariffs are aimed at ostensibly boosting US production and fostering a “local for locals” sensibility. Except, it turns out that several American product staples are actually... "Made in Europe"?

Euronews

Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income

Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.

Barchart

Pfizer Stock: Analyst Estimates & Ratings

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Barchart

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

The Guardian - UK

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma RD from the past look like it’s still sending lab results by fax. Down the…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

Benzinga

Under the Radar: Hidden Value Across the Atlantic – 3 Stocks to Watch

Here is what they are not talking about on CNBC right now.

AAP

Trade stand-off continues as US drug tariffs loom

The deadline on US pharmaceutical tariffs has been dramatically brought forward, in the latest escalation of Donald Trump's trade war with the world.

Benzinga

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Retirement Ready: 3 Dividend Stocks to Set and Forget

These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year after year.

MarketBeat

Don’t Miss These 4 Stocks With Explosive Dividend Yields

See which large-cap U.S. stocks offer the highest yields in healthcare, materials, utilities, and real estate. Their yields range from 6% to over 14%.

Benzinga

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer.

Benzinga

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) at high…

Benzinga

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Barchart

Wednesday’s Unusual Options Activity Reveals 3 Standout Long Straddle Plays

There were 37 unusually active options in Wednesday Trading that expire in 30 days. This DTE reveals three standout long straddle plays that provide a nice combination of time and cost, while allowing increased volatility to take its course.

The Independent UK

Ursula von der Leyen faces confidence vote in far-right challenge

A range of accusations have been levelled against the European Commission president

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.